This systematic review will be conducted to clarify essential details associated with anti-PD-1 and anti-PD-L1 drugs in the treatment of NSCLC and the findings of the review may facilitate early prediction, comprehensive observation, and prompt management of irAEs in addition to better patient compliance. The gene discussed is CD274; the disease is non-small cell lung carcinoma.